David Wormser
About
David Wormser is a scholar working on Public Health, Environmental and Occupational Health, Pathology and Forensic Medicine and Oncology.
According to data from OpenAlex, David Wormser has authored 21 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Public Health, Environmental and Occupational Health, 6 papers in Pathology and Forensic Medicine and 6 papers in Oncology. Recurrent topics in David Wormser's work include Acute Lymphoblastic Leukemia research (6 papers), Multiple Sclerosis Research Studies (6 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (4 papers). David Wormser is often cited by papers focused on Acute Lymphoblastic Leukemia research (6 papers), Multiple Sclerosis Research Studies (6 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (4 papers). David Wormser collaborates with scholars based in Switzerland, United States and United Kingdom. David Wormser's co-authors include Angela Wood, Qing Qiao, Majid Ezzati, Farshad Farzadfar, Emanuele Di Angelantonio, Mohammed K. Ali, Carlene M.M. Lawes, Goodarz Danaei, Gretchen A Stevens and Stephen Vander Hoorn and has published in prestigious journals such as The Lancet, Blood and PLoS ONE.
In The Last Decade
David Wormser
18 papers receiving 1.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| David Wormser Switzerland | 9 | 510 | 457 | 382 | 306 | 217 | 21 | 1.5k | ||
| Yuni Choi United States | 23 | 408 0.8× | 338 0.7× | 399 1.0× | 422 1.4× | 522 2.4× | 51 | 1.9k | ||
| Aurelian Bidulescu United States | 20 | 353 0.7× | 431 0.9× | 353 0.9× | 228 0.7× | 381 1.8× | 78 | 1.6k | ||
| Marieke B. Snijder Netherlands | 15 | 497 1.0× | 433 0.9× | 537 1.4× | 236 0.8× | 290 1.3× | 21 | 1.4k | ||
| Satoyo Ikehara Japan | 19 | 302 0.6× | 244 0.5× | 194 0.5× | 163 0.5× | 262 1.2× | 70 | 1.5k | ||
| Te‐Ching Chen United States | 12 | 364 0.7× | 259 0.6× | 227 0.6× | 234 0.8× | 211 1.0× | 16 | 1.3k | ||
| Ruby Jacobs Canada | 11 | 579 1.1× | 315 0.7× | 324 0.8× | 497 1.6× | 337 1.6× | 12 | 1.5k | ||
| Ana Carolina Junqueira Vasques Brazil | 18 | 437 0.9× | 385 0.8× | 497 1.3× | 763 2.5× | 462 2.1× | 70 | 1.9k | ||
| Chang Beom Lee South Korea | 14 | 460 0.9× | 240 0.5× | 395 1.0× | 518 1.7× | 301 1.4× | 56 | 1.7k | ||
| Grażyna Broda Poland | 22 | 358 0.7× | 510 1.1× | 181 0.5× | 247 0.8× | 185 0.9× | 84 | 1.4k | ||
| Joan E. Hilner United States | 21 | 792 1.6× | 348 0.8× | 425 1.1× | 459 1.5× | 213 1.0× | 34 | 2.1k |
Countries citing papers authored by David Wormser
Since
Specialization
Citations
This map shows the geographic impact of David Wormser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Wormser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Wormser more than expected).
Fields of papers citing papers by David Wormser
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by David Wormser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Wormser. The network helps show where David Wormser may publish in the future.
Co-authorship network of co-authors of David Wormser
This figure shows the co-authorship network connecting the top 25 collaborators of David Wormser. A scholar is included among the top collaborators of David Wormser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Wormser. David Wormser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Dahlén, Torsten, Germano Ferreira, Peter E. Westerweel, et al.. (2021). Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-World Evidence. Blood. 138(Supplement 1). 1485–1485.
2.
Wormser, David, et al.. (2021). Real-World Evaluation of the Treatment Landscape for Chronic Lymphocytic Leukemia. Blood. 138(Supplement 1). 1559–1559.
3.
Díez‐Campelo, María, Luis Benlloch, Emma Chen Sasse, et al.. (2021). Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry. Blood. 138(Supplement 1). 2605–2605.
4.
Burkill, Sarah, Ayako Hiyoshi, Tomas Olsson, et al.. (2020). Comorbid disease burden among MS patients 1968–2012: A Swedish register–based cohort study. Multiple Sclerosis Journal. 27(2). 268–280.
5.
Zingler, Vera Carina, et al.. (2020). Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts – the CONFIDENCE study protocol. BMC Neurology. 20(1). 95–95.
6.
Burkill, Sarah, Ayako Hiyoshi, Tomas Olsson, et al.. (2020). Comorbid disease burden among MS patients 1968–2012: A Swedish register–based cohort study. Sage Journals Data.
7.
Hauser, Stephen L., Ludwig Kappos, Xavier Montalbán, et al.. (2020). Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis. Multiple Sclerosis and Related Disorders. 37. 101589–101589.
8.
Hartung, Hans‐Peter, Ludwig Kappos, Xavier Montalbán, et al.. (2019). FV 47 Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Clinical Neurophysiology. 130(8). e142–e142.
9.
Wormser, David, et al.. (2018). Design of the Ocrelizumab Pregnancy Registry to Assess Maternal, Fetal and Infant Outcomes in Women With Multiple Sclerosis Who Were Exposed to Ocrelizumab During, or Within 6 Months Before, Pregnancy (P4.367). Neurology. 90(15_supplement).
10.
Nørgaard, Mette, et al.. (2018). Multiple sclerosis and cancer incidence: A Danish nationwide cohort study. Multiple Sclerosis and Related Disorders. 28. 81–85.
11.
Hauser, Stephen L., Ludwig Kappos, Xavier Montalbán, et al.. (2018). Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary progressive Multiple Sclerosis. Multiple Sclerosis and Related Disorders. 26. 264–264.
12.
Hauser, Stephen L., Ludwig Kappos, Xavier Montalbán, et al.. (2018). Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis (S36.001). Neurology. 90(15_supplement).
13.
Margulis, Andrea V., Elizabeth Andrews, Sonia Hernández–Dı́az, et al.. (2018). Design of a Multi-Source Post-Marketing Study to Evaluate Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Who Were Exposed to Ocrelizumab During, or Within 6 Months Before, Pregnancy (P4.372). Neurology. 90(15_supplement).
14.
Krueger, Whitney S., Mary S. Anthony, Andrea V. Margulis, et al.. (2017). Evaluating the Safety of Medication Exposures During Pregnancy: A Case Study of Study Designs and Data Sources in Multiple Sclerosis. Drugs - Real World Outcomes. 4(3). 139–149.
15.
Kappos, Ludwig, Stephen L. Hauser, Xavier Montalbán, et al.. (2017). Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis (P5.407). Neurology. 88(16_supplement).
16.
Stevens, June, Zhaohui Cui, Jianwen Cai, et al.. (2016). Cardiovascular disease risk by assigned treatment using the 2013 and 1998 obesity guidelines. Obesity. 24(7). 1554–1560.
17.
Singh, Gitanjali M, Goodarz Danaei, Farshad Farzadfar, et al.. (2013). The Age-Specific Quantitative Effects of Metabolic Risk Factors on Cardiovascular Diseases and Diabetes: A Pooled Analysis. PLoS ONE. 8(7). e65174–e65174.
18.
Wormser, David, Ian R. White, Simon G. Thompson, & Angela Wood. (2013). Within-person variability in calculated risk factors: Comparing the aetiological association of adiposity ratios with risk of coronary heart disease. International Journal of Epidemiology. 42(3). 849–859.
19.
Wormser, David, et al.. (2011). Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. The Lancet. 377(9771). 1085–1095.
20.
Wormser, David, Emanuele Di Angelantonio, Naveed Sattar, et al.. (2011). Body-mass index, abdominal adiposity, and cardiovascular risk – Authors' reply. The Lancet. 378(9787). 228–228.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Yuni Choi Breakdown of academic impact, for papers by Aurelian Bidulescu Breakdown of academic impact, for papers by Marieke B. Snijder Breakdown of academic impact, for papers by Satoyo Ikehara Breakdown of academic impact, for papers by Te‐Ching Chen Breakdown of academic impact, for papers by Ruby Jacobs Breakdown of academic impact, for papers by Ana Carolina Junqueira Vasques Breakdown of academic impact, for papers by Chang Beom Lee Breakdown of academic impact, for papers by Grażyna Broda Breakdown of academic impact, for papers by Joan E. Hilner